首页 > 最新文献

Anemia最新文献

英文 中文
Using Soluble Transferrin Receptor and Taking Inflammation into Account When Defining Serum Ferritin Cutoffs Improved the Diagnosis of Iron Deficiency in a Group of Canadian Preschool Inuit Children from Nunavik. 在确定血清铁蛋白切断时,使用可溶性转铁蛋白受体并考虑炎症改善了一组来自努那维克的加拿大学龄前因纽特儿童缺铁的诊断。
IF 2.9 Q3 HEMATOLOGY Pub Date : 2016-01-01 Epub Date: 2016-06-13 DOI: 10.1155/2016/6430214
Huguette Turgeon O'Brien, Rosanne Blanchet, Doris Gagné, Julie Lauzière, Carole Vézina

The prevalence of iron depletion, iron deficient erythropoiesis (IDE), and iron deficiency anemia (IDA) was assessed in preschool Inuit children using soluble transferrin receptor (sTfR) and traditional indicators of iron status while disregarding or taking inflammation into account when defining SF cutoffs. Iron depletion was defined as follows: (1) SF < 15 μg/L regardless of the C-reactive protein (CRP) level and (2) SF < 15 or <50 μg/L with CRP ≤ 5 or >5 mg/L, respectively. IDE corresponded to iron depletion combined with total iron binding capacity > 72 μmol/L and/or transferrin saturation < 16%. Iron depletion and IDE affected almost half of the children when accounting for inflammation, compared to one-third when the SF cutoff was defined regardless of CRP level (P < 0.0001). The prevalence of IDE adjusted for inflammation (45.1%) was very similar to the prevalence observed when sTfR was used as a sole marker of IDE (47.4%). The prevalence of anemia was 15%. The prevalence of IDA (IDE + hemoglobin < 110 g/L) was higher when accounting for than when disregarding inflammation (8.0% versus 6.2%, P = 0.083). Using sTfR and different SF cutoffs for children with versus without inflammation improved the diagnosis of iron depletion and IDE. Our results confirm that Inuit children are at particularly high risk for iron deficiency.

使用可溶性转铁蛋白受体(sTfR)和传统的铁状态指标评估因纽特学龄前儿童中铁耗尽、铁缺乏性红细胞(IDE)和缺铁性贫血(IDA)的患病率,在定义SF截止时忽略或考虑炎症。铁耗尽的定义如下:(1)无论c反应蛋白(CRP)水平如何,SF < 15 μg/L; (2) SF分别< 15或5 mg/L。IDE对应铁耗尽,总铁结合容量> 72 μmol/L和/或转铁蛋白饱和度< 16%。当考虑到炎症时,铁缺乏和IDE影响了几乎一半的儿童,而当定义SF截止时,无论CRP水平如何,这一比例为三分之一(P < 0.0001)。经炎症调整的IDE患病率(45.1%)与使用sTfR作为IDE的唯一标志物时观察到的患病率(47.4%)非常相似。贫血的患病率为15%。考虑炎症时,IDA (IDE +血红蛋白< 110 g/L)的患病率高于不考虑炎症时(8.0%对6.2%,P = 0.083)。对有无炎症的儿童使用sTfR和不同的SF截止值可改善铁耗尽和IDE的诊断。我们的研究结果证实,因纽特儿童缺铁的风险特别高。
{"title":"Using Soluble Transferrin Receptor and Taking Inflammation into Account When Defining Serum Ferritin Cutoffs Improved the Diagnosis of Iron Deficiency in a Group of Canadian Preschool Inuit Children from Nunavik.","authors":"Huguette Turgeon O'Brien,&nbsp;Rosanne Blanchet,&nbsp;Doris Gagné,&nbsp;Julie Lauzière,&nbsp;Carole Vézina","doi":"10.1155/2016/6430214","DOIUrl":"https://doi.org/10.1155/2016/6430214","url":null,"abstract":"<p><p>The prevalence of iron depletion, iron deficient erythropoiesis (IDE), and iron deficiency anemia (IDA) was assessed in preschool Inuit children using soluble transferrin receptor (sTfR) and traditional indicators of iron status while disregarding or taking inflammation into account when defining SF cutoffs. Iron depletion was defined as follows: (1) SF < 15 μg/L regardless of the C-reactive protein (CRP) level and (2) SF < 15 or <50 μg/L with CRP ≤ 5 or >5 mg/L, respectively. IDE corresponded to iron depletion combined with total iron binding capacity > 72 μmol/L and/or transferrin saturation < 16%. Iron depletion and IDE affected almost half of the children when accounting for inflammation, compared to one-third when the SF cutoff was defined regardless of CRP level (P < 0.0001). The prevalence of IDE adjusted for inflammation (45.1%) was very similar to the prevalence observed when sTfR was used as a sole marker of IDE (47.4%). The prevalence of anemia was 15%. The prevalence of IDA (IDE + hemoglobin < 110 g/L) was higher when accounting for than when disregarding inflammation (8.0% versus 6.2%, P = 0.083). Using sTfR and different SF cutoffs for children with versus without inflammation improved the diagnosis of iron depletion and IDE. Our results confirm that Inuit children are at particularly high risk for iron deficiency. </p>","PeriodicalId":46055,"journal":{"name":"Anemia","volume":"2016 ","pages":"6430214"},"PeriodicalIF":2.9,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2016/6430214","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34641113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 16
Transfusion Thresholds, Quality of Life, and Current Approaches in Myelodysplastic Syndromes. 骨髓增生异常综合征的输血阈值、生活质量和当前治疗方法。
IF 2.9 Q3 HEMATOLOGY Pub Date : 2016-01-01 Epub Date: 2016-04-19 DOI: 10.1155/2016/8494738
Ioannis Koutsavlis

Hemoglobin thresholds and triggers for blood transfusions have changed over the years moving from a higher to a lower level. This review article summarizes the current evidence of transfusion thresholds in the hospitalized as well as in the outpatient setting and particularly in myelodysplasia. Fatigue is the main reported symptom in this group of patients and current clinical trials are looking for a more liberal approach of red cell transfusion and the effect on quality of life as opposed to the restrictive strategy used in the critical care setting. Practical considerations, the cost effectiveness of this strategy in addition to the possible complications, and the use of quality of life questionnaires have also been reviewed.

多年来,血红蛋白阈值和输血触发因素发生了变化,从较高的水平到较低的水平。这篇综述文章总结了输血阈值在住院和门诊的现有证据,特别是在骨髓增生异常。疲劳是这组患者报告的主要症状,目前的临床试验正在寻找一种更自由的红细胞输注方法及其对生活质量的影响,而不是在重症监护环境中使用的限制性策略。还审查了实际考虑因素、这一战略的成本效益以及可能的并发症和生活质量调查表的使用。
{"title":"Transfusion Thresholds, Quality of Life, and Current Approaches in Myelodysplastic Syndromes.","authors":"Ioannis Koutsavlis","doi":"10.1155/2016/8494738","DOIUrl":"https://doi.org/10.1155/2016/8494738","url":null,"abstract":"<p><p>Hemoglobin thresholds and triggers for blood transfusions have changed over the years moving from a higher to a lower level. This review article summarizes the current evidence of transfusion thresholds in the hospitalized as well as in the outpatient setting and particularly in myelodysplasia. Fatigue is the main reported symptom in this group of patients and current clinical trials are looking for a more liberal approach of red cell transfusion and the effect on quality of life as opposed to the restrictive strategy used in the critical care setting. Practical considerations, the cost effectiveness of this strategy in addition to the possible complications, and the use of quality of life questionnaires have also been reviewed. </p>","PeriodicalId":46055,"journal":{"name":"Anemia","volume":"2016 ","pages":"8494738"},"PeriodicalIF":2.9,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2016/8494738","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34394183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 25
The Cost-Effectiveness of Continuous Erythropoiesis Receptor Activator Once Monthly versus Epoetin Thrice Weekly for Anaemia Management in Chronic Haemodialysis Patients 慢性血液透析患者每月1次连续使用红细胞生成受体激活剂与每周3次生成素治疗贫血的成本-效果比较
IF 2.9 Q3 HEMATOLOGY Pub Date : 2015-12-30 DOI: 10.1155/2015/189404
O. Maoujoud, S. Ahid, H. Dkhissi, Z. Oualim, Y. Cherrah
Introduction. The aim of this study was to compare the cost-effectiveness of continuous erythropoietin receptor activator (CERA) once monthly to epoetin beta (EpoB) thrice weekly to maintain haemoglobin (Hb) within the range 10.5–12 g/dL. Methods. Prospective cohort study and cost-effectiveness analysis. Chronic haemodialysis patients (CHP), being treated with EpoB, were selected for two periods of follow-up: period 1, maintaining prior treatment with EpoB, and period 2, conversion to CERA once monthly. Hb concentrations and costs were measured monthly. Health care payer perspective for one year was adopted. Results. 75 CHP completed the study, with a mean age of 52.9 ± 14.3 years. Baseline Hb was 11.14 ± 1.18 g/dL in EpoB phase and 11.46 ± 0.79 g/dL in CERA phase; we observed a significant increase in the proportion of patients successfully treated (Hb within the recommended range), 65.3% versus 70.7%, p: 0.008, and in the average effectiveness by 4% (0.55 versus 0.59). Average cost-effectiveness ratios were 6013.86 and 5173.64$, with an ICER CERA to EpoB at −6457.5$. Conclusion. Our health economic evaluation of ESA use in haemodialysis patients suggests that the use of CERA is cost-effective compared with EpoB.
介绍。本研究的目的是比较每月1次的持续促红细胞生成素受体激活剂(CERA)和每周3次的促红细胞生成素β (EpoB)的成本-效果,以维持血红蛋白(Hb)在10.5-12 g/dL范围内。方法。前瞻性队列研究及成本-效果分析。选择接受EpoB治疗的慢性血液透析患者(CHP)进行两期随访:第一期,维持先前的EpoB治疗,第二期,转换为CERA每月一次。每月测量Hb浓度和成本。采用为期一年的医疗保健支付者视角。结果:75例CHP完成研究,平均年龄52.9±14.3岁。EpoB期基线Hb为11.14±1.18 g/dL, CERA期基线Hb为11.46±0.79 g/dL;我们观察到成功治疗的患者比例(Hb在推荐范围内)显著增加,65.3%对70.7%,p: 0.008,平均有效性增加4%(0.55对0.59)。平均成本效益比为6013.86美元和5173.64美元,ICER CERA与EpoB的成本效益比为- 6457.5美元。结论。我们对血液透析患者使用ESA的健康经济评估表明,与EpoB相比,使用CERA具有成本效益。
{"title":"The Cost-Effectiveness of Continuous Erythropoiesis Receptor Activator Once Monthly versus Epoetin Thrice Weekly for Anaemia Management in Chronic Haemodialysis Patients","authors":"O. Maoujoud, S. Ahid, H. Dkhissi, Z. Oualim, Y. Cherrah","doi":"10.1155/2015/189404","DOIUrl":"https://doi.org/10.1155/2015/189404","url":null,"abstract":"Introduction. The aim of this study was to compare the cost-effectiveness of continuous erythropoietin receptor activator (CERA) once monthly to epoetin beta (EpoB) thrice weekly to maintain haemoglobin (Hb) within the range 10.5–12 g/dL. Methods. Prospective cohort study and cost-effectiveness analysis. Chronic haemodialysis patients (CHP), being treated with EpoB, were selected for two periods of follow-up: period 1, maintaining prior treatment with EpoB, and period 2, conversion to CERA once monthly. Hb concentrations and costs were measured monthly. Health care payer perspective for one year was adopted. Results. 75 CHP completed the study, with a mean age of 52.9 ± 14.3 years. Baseline Hb was 11.14 ± 1.18 g/dL in EpoB phase and 11.46 ± 0.79 g/dL in CERA phase; we observed a significant increase in the proportion of patients successfully treated (Hb within the recommended range), 65.3% versus 70.7%, p: 0.008, and in the average effectiveness by 4% (0.55 versus 0.59). Average cost-effectiveness ratios were 6013.86 and 5173.64$, with an ICER CERA to EpoB at −6457.5$. Conclusion. Our health economic evaluation of ESA use in haemodialysis patients suggests that the use of CERA is cost-effective compared with EpoB.","PeriodicalId":46055,"journal":{"name":"Anemia","volume":"2015 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2015-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/189404","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"64832554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Hyperglycaemic Environment: Contribution to the Anaemia Associated with Diabetes Mellitus in Rats Experimentally Induced with Alloxan 高血糖环境:对四氧嘧啶诱导的大鼠与糖尿病相关的贫血的贡献
IF 2.9 Q3 HEMATOLOGY Pub Date : 2015-11-30 DOI: 10.1155/2015/848921
Oseni Bashiru Shola, Fakoya Olatunde Olugbenga
Background. Diabetes mellitus characterized by hyperglycaemia presents with various complications amongst which anaemia is common particularly in those with overt nephropathy or renal impairment. The present study has examined the contribution of the hyperglycaemic environment in diabetic rats to the anaemia associated with diabetes mellitus. Method. Sixty male albino rats weighing 175–250 g were selected for this study and divided equally into control and test groups. Hyperglycaemia was induced with 170 kgbwt−1 alloxan intraperitoneally in the test group while control group received sterile normal saline. Blood samples obtained from the control and test rats were assayed for packed cell volume (PCV), haemoglobin (Hb), red blood cell count (RBC), reticulocyte count, glucose, plasma haemoglobin, potassium, and bilirubin. Result. Significant reduction (P < 0.01) in PCV (24.40 ± 3.87 versus 40.45 ± 3.93) and haemoglobin (7.81 ± 1.45 versus 13.39 ± 0.40) with significant increase (P < 0.01) in reticulocyte count (12.4 ± 1.87 versus 3.69 ± 0.47), plasma haemoglobin (67.50 ± 10.85 versus 34.20 ± 3.83), and potassium (7.04 ± 0.75 versus 4.52 ± 0.63) was obtained in the test while plasma bilirubin showed nonsignificant increase (0.41 ± 0.04 versus 0.24 ± 0.06). Conclusion. The increased plasma haemoglobin and potassium levels indicate an intravascular haemolytic event while the nonsignificant increased bilirubin showed extravascular haemolysis. These play contributory roles in the anaemia associated with diabetes mellitus.
背景。糖尿病以高血糖为特征,伴有各种并发症,其中贫血是常见的,特别是在那些有明显肾病或肾功能损害的患者中。本研究探讨了糖尿病大鼠的高血糖环境对糖尿病相关性贫血的影响。方法。选取体重175 ~ 250 g的雄性白化大鼠60只,平均分为对照组和试验组。实验组腹腔注射170 kgbwt−1四氧嘧啶诱导高血糖,对照组腹腔注射无菌生理盐水。从对照和试验大鼠获得的血液样本进行堆积细胞体积(PCV)、血红蛋白(Hb)、红细胞计数(RBC)、网织红细胞计数、葡萄糖、血浆血红蛋白、钾和胆红素的测定。结果。PCV(24.40±3.87比40.45±3.93)、血红蛋白(7.81±1.45比13.39±0.40)显著降低(P < 0.01),网网红细胞计数(12.4±1.87比3.69±0.47)、血浆血红蛋白(67.50±10.85比34.20±3.83)、钾(7.04±0.75比4.52±0.63)显著增加(P < 0.01),血浆胆红素(0.41±0.04比0.24±0.06)无显著升高(P < 0.01)。结论。血浆血红蛋白和钾水平升高提示血管内溶血事件,而胆红素不显著升高提示血管外溶血。这些在与糖尿病相关的贫血中起促进作用。
{"title":"Hyperglycaemic Environment: Contribution to the Anaemia Associated with Diabetes Mellitus in Rats Experimentally Induced with Alloxan","authors":"Oseni Bashiru Shola, Fakoya Olatunde Olugbenga","doi":"10.1155/2015/848921","DOIUrl":"https://doi.org/10.1155/2015/848921","url":null,"abstract":"Background. Diabetes mellitus characterized by hyperglycaemia presents with various complications amongst which anaemia is common particularly in those with overt nephropathy or renal impairment. The present study has examined the contribution of the hyperglycaemic environment in diabetic rats to the anaemia associated with diabetes mellitus. Method. Sixty male albino rats weighing 175–250 g were selected for this study and divided equally into control and test groups. Hyperglycaemia was induced with 170 kgbwt−1 alloxan intraperitoneally in the test group while control group received sterile normal saline. Blood samples obtained from the control and test rats were assayed for packed cell volume (PCV), haemoglobin (Hb), red blood cell count (RBC), reticulocyte count, glucose, plasma haemoglobin, potassium, and bilirubin. Result. Significant reduction (P < 0.01) in PCV (24.40 ± 3.87 versus 40.45 ± 3.93) and haemoglobin (7.81 ± 1.45 versus 13.39 ± 0.40) with significant increase (P < 0.01) in reticulocyte count (12.4 ± 1.87 versus 3.69 ± 0.47), plasma haemoglobin (67.50 ± 10.85 versus 34.20 ± 3.83), and potassium (7.04 ± 0.75 versus 4.52 ± 0.63) was obtained in the test while plasma bilirubin showed nonsignificant increase (0.41 ± 0.04 versus 0.24 ± 0.06). Conclusion. The increased plasma haemoglobin and potassium levels indicate an intravascular haemolytic event while the nonsignificant increased bilirubin showed extravascular haemolysis. These play contributory roles in the anaemia associated with diabetes mellitus.","PeriodicalId":46055,"journal":{"name":"Anemia","volume":"60 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2015-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/848921","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65182619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Prevalence and Risk Factors for Complications in Patients with Nontransfusion Dependent Alpha- and Beta-Thalassemia 非输血依赖性α -和β -地中海贫血患者并发症的患病率和危险因素
IF 2.9 Q3 HEMATOLOGY Pub Date : 2015-11-18 DOI: 10.1155/2015/793025
P. Winichakoon, A. Tantiworawit, T. Rattanathammethee, S. Hantrakool, C. Chai-Adisaksopha, E. Rattarittamrong, L. Norasetthada, P. Charoenkwan
Background. Nontransfusion dependent thalassemia (NTDT) is a milder form of thalassemia that does not require regular transfusion. It is associated with many complications, which differ from that found in transfusion-dependent thalassemia (TDT). Currently available information is mostly derived from beta-NTDT; consequently, more data is needed to describe complications found in the alpha-NTDT form of this disease. Methods. We retrospectively reviewed the medical records of NTDT patients from January 2012 to December 2013. Complications related to thalassemia were reviewed and compared. Results. One hundred patients included 60 females with a median age of 38 years. The majority (54 patients) had alpha-thalassemia. Overall, 83 patients had one or more complications. The three most common complications were cholelithiasis (35%), abnormal liver function (29%), and extramedullary hematopoiesis (EMH) (25%). EMH, cardiomyopathy, cholelithiasis, and pulmonary hypertension were more commonly seen in beta-thalassemia. Osteoporosis was the only complication that was more common in alpha-thalassemia. The risk factors significantly related to EMH were beta-thalassemia type and hemoglobin < 8 g/dL. The risk factors related to osteoporosis were female gender and age > 40 years. Iron overload (ferritin > 800 ng/mL) was the only risk factor for abnormal liver function. Conclusion. The prevalence of alpha-NTDT complications was lower and different from beta-thalassemia.
背景。非输血依赖型地中海贫血(NTDT)是一种不需要定期输血的较轻形式的地中海贫血。它与许多并发症有关,这些并发症与输血依赖型地中海贫血(TDT)不同。目前可获得的信息主要来自β - ntdt;因此,需要更多的数据来描述这种疾病的α - ntdt形式的并发症。方法。我们回顾性回顾了2012年1月至2013年12月NTDT患者的医疗记录。对地中海贫血的并发症进行了回顾和比较。结果。100例患者包括60例女性,中位年龄38岁。大多数(54例)患有α -地中海贫血。总的来说,83名患者有一种或多种并发症。最常见的三种并发症是胆石症(35%)、肝功能异常(29%)和髓外造血(EMH)(25%)。EMH、心肌病、胆石症和肺动脉高压在-地中海贫血中更为常见。骨质疏松症是唯一在地中海贫血中更常见的并发症。与EMH显著相关的危险因素为-地中海贫血型和血红蛋白< 8 g/dL。与骨质疏松相关的危险因素为女性、性别和年龄(0 ~ 40岁)。铁超载(铁蛋白> 800 ng/mL)是肝功能异常的唯一危险因素。结论。α - ntdt并发症的发生率较低,与β -地中海贫血不同。
{"title":"Prevalence and Risk Factors for Complications in Patients with Nontransfusion Dependent Alpha- and Beta-Thalassemia","authors":"P. Winichakoon, A. Tantiworawit, T. Rattanathammethee, S. Hantrakool, C. Chai-Adisaksopha, E. Rattarittamrong, L. Norasetthada, P. Charoenkwan","doi":"10.1155/2015/793025","DOIUrl":"https://doi.org/10.1155/2015/793025","url":null,"abstract":"Background. Nontransfusion dependent thalassemia (NTDT) is a milder form of thalassemia that does not require regular transfusion. It is associated with many complications, which differ from that found in transfusion-dependent thalassemia (TDT). Currently available information is mostly derived from beta-NTDT; consequently, more data is needed to describe complications found in the alpha-NTDT form of this disease. Methods. We retrospectively reviewed the medical records of NTDT patients from January 2012 to December 2013. Complications related to thalassemia were reviewed and compared. Results. One hundred patients included 60 females with a median age of 38 years. The majority (54 patients) had alpha-thalassemia. Overall, 83 patients had one or more complications. The three most common complications were cholelithiasis (35%), abnormal liver function (29%), and extramedullary hematopoiesis (EMH) (25%). EMH, cardiomyopathy, cholelithiasis, and pulmonary hypertension were more commonly seen in beta-thalassemia. Osteoporosis was the only complication that was more common in alpha-thalassemia. The risk factors significantly related to EMH were beta-thalassemia type and hemoglobin < 8 g/dL. The risk factors related to osteoporosis were female gender and age > 40 years. Iron overload (ferritin > 800 ng/mL) was the only risk factor for abnormal liver function. Conclusion. The prevalence of alpha-NTDT complications was lower and different from beta-thalassemia.","PeriodicalId":46055,"journal":{"name":"Anemia","volume":"2015 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2015-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/793025","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65150424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 17
Anemia in Patients with Type 2 Diabetes Mellitus 2型糖尿病患者的贫血
IF 2.9 Q3 HEMATOLOGY Pub Date : 2015-11-11 DOI: 10.1155/2015/354737
J. Barbieri, P. C. Fontela, E. R. Winkelmann, C. Zimmermann, Yana Picinin Sandri, Emanelle Kerber Viera Mallet, M. Frizzo
The objective of this study was to evaluate the prevalence of anemia in DM2 patients and its correlation with demographic and lifestyle and laboratory variables. This is a descriptive and analytical study of the type of case studies in the urban area of the Ijuí city, registered in programs of the Family Health Strategy, with a total sample of 146 patients with DM2. A semistructured questionnaire with sociodemographic and clinical variables and performed biochemical test was applied. Of the DM2 patients studied, 50 patients had anemia, and it was found that the body mass items and hypertension and hematological variables are significantly associated with anemia of chronic disease. So, the prevalence of anemia is high in patients with DM2. The set of observed changes characterizes the anemia of chronic disease, which affects quality of life of diabetic patients and is associated with disease progression, development, and comorbidities that contribute significantly to increasing the risk of cardiovascular diseases.
本研究的目的是评估DM2患者贫血的患病率及其与人口统计学、生活方式和实验室变量的相关性。这是一项对Ijuí城市地区案例研究类型的描述性和分析性研究,在家庭保健战略方案中登记,共抽样146名DM2患者。采用包含社会人口学和临床变量的半结构化问卷,并进行生化检验。在研究的DM2患者中,有50例患者出现贫血,发现体重项目、高血压和血液学变量与慢性病贫血有显著相关性。因此,DM2患者贫血的患病率很高。这组观察到的变化是慢性疾病贫血的特征,它影响糖尿病患者的生活质量,并与疾病进展、发展和合并症相关,从而显著增加心血管疾病的风险。
{"title":"Anemia in Patients with Type 2 Diabetes Mellitus","authors":"J. Barbieri, P. C. Fontela, E. R. Winkelmann, C. Zimmermann, Yana Picinin Sandri, Emanelle Kerber Viera Mallet, M. Frizzo","doi":"10.1155/2015/354737","DOIUrl":"https://doi.org/10.1155/2015/354737","url":null,"abstract":"The objective of this study was to evaluate the prevalence of anemia in DM2 patients and its correlation with demographic and lifestyle and laboratory variables. This is a descriptive and analytical study of the type of case studies in the urban area of the Ijuí city, registered in programs of the Family Health Strategy, with a total sample of 146 patients with DM2. A semistructured questionnaire with sociodemographic and clinical variables and performed biochemical test was applied. Of the DM2 patients studied, 50 patients had anemia, and it was found that the body mass items and hypertension and hematological variables are significantly associated with anemia of chronic disease. So, the prevalence of anemia is high in patients with DM2. The set of observed changes characterizes the anemia of chronic disease, which affects quality of life of diabetic patients and is associated with disease progression, development, and comorbidities that contribute significantly to increasing the risk of cardiovascular diseases.","PeriodicalId":46055,"journal":{"name":"Anemia","volume":"2015 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2015-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/354737","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"64917388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 76
Hospitalization Events among Children and Adolescents with Sickle Cell Disease in Basra, Iraq 伊拉克巴士拉镰状细胞病儿童和青少年住院事件
IF 2.9 Q3 HEMATOLOGY Pub Date : 2015-10-26 DOI: 10.1155/2015/195469
Z. Salman, M. Hassan
Objectives. Despite improvements in the management of sickle cell disease (SCD), many patients still experience disease-related complications requiring hospitalizations. The objectives of this study were to identify causes of hospitalization among these patients and factors associated with the length of hospital stay (LOS) and readmission. Methods. Data from 160 patients (<14 years old) with SCD who were admitted to the Basra Maternity and Children's Hospital from the first of January 2012 through July 2012 were analyzed. Results. The main causes of hospitalization were acute painful crises (73.84%), infections (9.28%), acute chest syndrome (8.02%), and acute splenic sequestration crisis (6.32%). The mean LOS was 4.34 ± 2.85 days. The LOS for patients on hydroxyurea (3.41 ± 2.64 days) was shorter than that for patients who were not (4.59 ± 2.86 days), P < 0.05. The readmission rate (23.1%) was significantly higher among patients with frequent hospitalizations in the previous year (OR 9.352, 95% CI 2.011–43.49), asthma symptoms (OR 4.225, 95% CI 1.125–15.862), and opioid use (OR 6.588, 95% CI 1.104–30.336). Patients on hydroxyurea were less likely to be readmitted (OR 0.082, 95% CI 0.10–0.663). Conclusions. There is a relatively high readmission rate among patients with SCD in Basra. The use of hydroxyurea significantly decreases the LOS and readmission rate.
目标。尽管镰状细胞病(SCD)的管理有所改善,但许多患者仍然经历与疾病相关的并发症,需要住院治疗。本研究的目的是确定这些患者住院的原因以及与住院时间(LOS)和再入院相关的因素。方法。对2012年1月1日至2012年7月在巴士拉妇幼医院住院的160名SCD患者(<14岁)的数据进行分析。结果。住院原因主要为急性疼痛危像(73.84%)、感染(9.28%)、急性胸综合征(8.02%)、急性脾隔离危像(6.32%)。平均生存时间(LOS)为4.34±2.85天。服用羟脲组的生存时间(3.41±2.64 d)短于未服用羟脲组(4.59±2.86 d), P < 0.05。前一年频繁住院的患者再入院率(23.1%)显著高于哮喘症状(OR 4.225, 95% CI 1.125-15.862)和阿片类药物使用(OR 6.588, 95% CI 1.104-30.336)。羟基脲组患者再入院的可能性较低(OR 0.082, 95% CI 0.10-0.663)。结论。在巴士拉,SCD患者的再入院率相对较高。羟基脲的使用显著降低了LOS和再入院率。
{"title":"Hospitalization Events among Children and Adolescents with Sickle Cell Disease in Basra, Iraq","authors":"Z. Salman, M. Hassan","doi":"10.1155/2015/195469","DOIUrl":"https://doi.org/10.1155/2015/195469","url":null,"abstract":"Objectives. Despite improvements in the management of sickle cell disease (SCD), many patients still experience disease-related complications requiring hospitalizations. The objectives of this study were to identify causes of hospitalization among these patients and factors associated with the length of hospital stay (LOS) and readmission. Methods. Data from 160 patients (<14 years old) with SCD who were admitted to the Basra Maternity and Children's Hospital from the first of January 2012 through July 2012 were analyzed. Results. The main causes of hospitalization were acute painful crises (73.84%), infections (9.28%), acute chest syndrome (8.02%), and acute splenic sequestration crisis (6.32%). The mean LOS was 4.34 ± 2.85 days. The LOS for patients on hydroxyurea (3.41 ± 2.64 days) was shorter than that for patients who were not (4.59 ± 2.86 days), P < 0.05. The readmission rate (23.1%) was significantly higher among patients with frequent hospitalizations in the previous year (OR 9.352, 95% CI 2.011–43.49), asthma symptoms (OR 4.225, 95% CI 1.125–15.862), and opioid use (OR 6.588, 95% CI 1.104–30.336). Patients on hydroxyurea were less likely to be readmitted (OR 0.082, 95% CI 0.10–0.663). Conclusions. There is a relatively high readmission rate among patients with SCD in Basra. The use of hydroxyurea significantly decreases the LOS and readmission rate.","PeriodicalId":46055,"journal":{"name":"Anemia","volume":"2015 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2015-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/195469","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"64836294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 18
Intravenous Iron Therapy in Patients with Iron Deficiency Anemia: Dosing Considerations. 缺铁性贫血患者的静脉铁剂治疗:用药注意事项。
IF 2.9 Q3 HEMATOLOGY Pub Date : 2015-01-01 Epub Date: 2015-07-15 DOI: 10.1155/2015/763576
Todd A Koch, Jennifer Myers, Lawrence Tim Goodnough

Objective. To provide clinicians with evidence-based guidance for iron therapy dosing in patients with iron deficiency anemia (IDA), we conducted a study examining the benefits of a higher cumulative dose of intravenous (IV) iron than what is typically administered. Methods. We first individually analyzed 5 clinical studies, averaging the total iron deficit across all patients utilizing a modified Ganzoni formula; we then similarly analyzed 2 larger clinical studies. For the second of the larger studies (Study 7), we also compared the efficacy and retreatment requirements of a cumulative dose of 1500 mg ferric carboxymaltose (FCM) to 1000 mg iron sucrose (IS). Results. The average iron deficit was calculated to be 1531 mg for patients in Studies 1-5 and 1392 mg for patients in Studies 6-7. The percentage of patients who were retreated with IV iron between Days 56 and 90 was significantly (p < 0.001) lower (5.6%) in the 1500 mg group, compared to the 1000 mg group (11.1%). Conclusions. Our data suggests that a total cumulative dose of 1000 mg of IV iron may be insufficient for iron repletion in a majority of patients with IDA and a dose of 1500 mg is closer to the actual iron deficit in these patients.

研究目的为了给临床医生提供缺铁性贫血(IDA)患者铁剂治疗剂量的循证指导,我们开展了一项研究,探讨静脉注射(IV)铁剂的累积剂量高于通常剂量的益处。研究方法我们首先对 5 项临床研究进行了单独分析,利用改进的甘佐尼公式计算出所有患者的总铁缺乏量的平均值;然后对 2 项更大型的临床研究进行了类似分析。在第二项大型研究(研究 7)中,我们还比较了累积剂量为 1500 毫克羧甲基铁(FCM)和 1000 毫克蔗糖铁(IS)的疗效和再治疗要求。结果。经计算,研究 1-5 的患者平均缺铁量为 1531 毫克,研究 6-7 的患者平均缺铁量为 1392 毫克。与 1000 毫克组(11.1%)相比,1500 毫克组(5.6%)在第 56 天至 90 天期间接受静脉注射铁剂治疗的患者比例明显降低(p < 0.001)。结论我们的数据表明,对于大多数 IDA 患者来说,1000 毫克的静脉注射铁剂累积总剂量可能不足以补铁,而 1500 毫克的剂量更接近这些患者的实际铁缺乏量。
{"title":"Intravenous Iron Therapy in Patients with Iron Deficiency Anemia: Dosing Considerations.","authors":"Todd A Koch, Jennifer Myers, Lawrence Tim Goodnough","doi":"10.1155/2015/763576","DOIUrl":"10.1155/2015/763576","url":null,"abstract":"<p><p>Objective. To provide clinicians with evidence-based guidance for iron therapy dosing in patients with iron deficiency anemia (IDA), we conducted a study examining the benefits of a higher cumulative dose of intravenous (IV) iron than what is typically administered. Methods. We first individually analyzed 5 clinical studies, averaging the total iron deficit across all patients utilizing a modified Ganzoni formula; we then similarly analyzed 2 larger clinical studies. For the second of the larger studies (Study 7), we also compared the efficacy and retreatment requirements of a cumulative dose of 1500 mg ferric carboxymaltose (FCM) to 1000 mg iron sucrose (IS). Results. The average iron deficit was calculated to be 1531 mg for patients in Studies 1-5 and 1392 mg for patients in Studies 6-7. The percentage of patients who were retreated with IV iron between Days 56 and 90 was significantly (p < 0.001) lower (5.6%) in the 1500 mg group, compared to the 1000 mg group (11.1%). Conclusions. Our data suggests that a total cumulative dose of 1000 mg of IV iron may be insufficient for iron repletion in a majority of patients with IDA and a dose of 1500 mg is closer to the actual iron deficit in these patients. </p>","PeriodicalId":46055,"journal":{"name":"Anemia","volume":"2015 ","pages":"763576"},"PeriodicalIF":2.9,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4518169/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33908955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reproductive and Obstetric Factors Are Key Predictors of Maternal Anemia during Pregnancy in Ethiopia: Evidence from Demographic and Health Survey (2011). 生殖和产科因素是埃塞俄比亚怀孕期间孕产妇贫血的关键预测因素:来自人口与健康调查的证据(2011年)。
IF 2.9 Q3 HEMATOLOGY Pub Date : 2015-01-01 Epub Date: 2015-08-31 DOI: 10.1155/2015/649815
Taddese Alemu, Melaku Umeta

Anemia is a major public health problem worldwide. In Ethiopia, a nationally representative and consistent evidence is lacking on the prevalence and determinants during pregnancy. We conducted an in-depth analysis of demographic and health survey for the year 2011 which is a representative data collected from all regions in Ethiopia. Considering maternal anemia as an outcome variable, predicting variables from sociodemographic, household, and reproductive/obstetric characteristics were identified for analyses. Logistic regression model was applied to identify predictors at P < 0.05. The prevalence of anemia among pregnant women was 23%. Maternal age, region, pregnancy trimester, number of under five children, previous history of abortion (termination of pregnancy), breastfeeding practices, and number of antenatal care visits were key independent predictors of anemia during pregnancy. In conclusion, the level of anemia during pregnancy is a moderate public health problem in Ethiopia. Yet, special preventive measures should be undertaken for pregnant women who are older in age and having too many under five children and previous history of abortion. Further evidence is expected to be generated concerning why pregnant mothers from the eastern part of the country and those with better access to radio disproportionately develop anemia more than their counterparts.

贫血是世界范围内的一个主要公共卫生问题。在埃塞俄比亚,缺乏关于怀孕期间患病率和决定因素的具有全国代表性和一致的证据。我们对2011年人口和健康调查进行了深入分析,这是从埃塞俄比亚所有地区收集的具有代表性的数据。考虑到产妇贫血作为结果变量,从社会人口统计学、家庭和生殖/产科特征中确定预测变量进行分析。采用Logistic回归模型识别预测因子,P < 0.05。孕妇贫血的患病率为23%。产妇年龄、地区、妊娠三个月、五岁以下儿童数量、流产史(终止妊娠)、母乳喂养习惯和产前检查次数是妊娠期间贫血的主要独立预测因素。最后,在埃塞俄比亚,怀孕期间的贫血程度是一个中等程度的公共卫生问题。然而,对于年龄较大、五岁以下儿童过多和有堕胎史的孕妇,应采取特别预防措施。预计将有进一步的证据表明,为什么来自该国东部地区和能够更好地获得无线电的孕妇比她们的同行更容易患上贫血症。
{"title":"Reproductive and Obstetric Factors Are Key Predictors of Maternal Anemia during Pregnancy in Ethiopia: Evidence from Demographic and Health Survey (2011).","authors":"Taddese Alemu,&nbsp;Melaku Umeta","doi":"10.1155/2015/649815","DOIUrl":"https://doi.org/10.1155/2015/649815","url":null,"abstract":"<p><p>Anemia is a major public health problem worldwide. In Ethiopia, a nationally representative and consistent evidence is lacking on the prevalence and determinants during pregnancy. We conducted an in-depth analysis of demographic and health survey for the year 2011 which is a representative data collected from all regions in Ethiopia. Considering maternal anemia as an outcome variable, predicting variables from sociodemographic, household, and reproductive/obstetric characteristics were identified for analyses. Logistic regression model was applied to identify predictors at P < 0.05. The prevalence of anemia among pregnant women was 23%. Maternal age, region, pregnancy trimester, number of under five children, previous history of abortion (termination of pregnancy), breastfeeding practices, and number of antenatal care visits were key independent predictors of anemia during pregnancy. In conclusion, the level of anemia during pregnancy is a moderate public health problem in Ethiopia. Yet, special preventive measures should be undertaken for pregnant women who are older in age and having too many under five children and previous history of abortion. Further evidence is expected to be generated concerning why pregnant mothers from the eastern part of the country and those with better access to radio disproportionately develop anemia more than their counterparts. </p>","PeriodicalId":46055,"journal":{"name":"Anemia","volume":"2015 ","pages":"649815"},"PeriodicalIF":2.9,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/649815","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34113219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 32
Efficacy and Safety of Intravenous Ferric Carboxymaltose in Geriatric Inpatients at a German Tertiary University Teaching Hospital: A Retrospective Observational Cohort Study of Clinical Practice. 德国第三大学教学医院老年住院患者静脉注射羧基麦芽糖铁的疗效和安全性:临床实践的回顾性观察队列研究。
IF 2.9 Q3 HEMATOLOGY Pub Date : 2015-01-01 Epub Date: 2015-07-05 DOI: 10.1155/2015/647930
Matthias Bach, Tabea Geisel, Julia Martin, Bettina Schulze, Roland Schaefer, Garth Virgin, Juergen Stein
Current iron supplementation practice in geriatric patients is erratic and lacks evidence-based recommendations. Despite potential benefits in this population, intravenous iron supplementation is often withheld due to concerns regarding pharmacy expense, perceived safety issues, and doubts regarding efficacy in elderly patients. This retrospective, observational cohort study aimed to evaluate the safety and efficacy of intravenous ferric carboxymaltose (FCM, Ferinject) in patients aged >75 years with iron deficiency anaemia (IDA). Within a twelve-month data extraction period, the charts of 405 hospitalised patients aged 65–101 years were retrospectively analysed for IDA, defined according to WHO criteria for anaemia (haemoglobin: <13.0 g/dL (m)/<12.0 g/dL (f)) in conjunction with transferrin saturation <20%. Of 128 IDA patients screened, 51 (39.8%) received intravenous iron. 38 patient charts were analysed. Mean cumulative dose of intravenous FCM was 784.4 ± 271.7 mg iron (1–3 infusions). 18 patients (47%) fulfilled treatment response criteria (≥1.0 g/dL increase in haemoglobin between baseline and hospital discharge). AEs were mild/moderate, most commonly transient increases of liver enzymes (n = 5/13.2%). AE incidence was comparable with that observed in patients <75 years. No serious AEs were observed. Ferric carboxymaltose was well tolerated and effective for correction of Hb levels and iron stores in this cohort of IDA patients aged over 75 years.
目前老年患者的补铁实践是不稳定的,缺乏循证建议。尽管在这一人群中有潜在的益处,但由于考虑到药房费用、可感知的安全性问题以及对老年患者疗效的怀疑,静脉补铁经常被拒绝。这项回顾性、观察性队列研究旨在评估静脉注射三羧基麦芽糖铁(FCM, Ferinject)治疗75岁以上缺铁性贫血(IDA)患者的安全性和有效性。在12个月的数据提取期内,对405例65-101岁住院患者的图表进行回顾性分析,根据世卫组织贫血标准(血红蛋白:
{"title":"Efficacy and Safety of Intravenous Ferric Carboxymaltose in Geriatric Inpatients at a German Tertiary University Teaching Hospital: A Retrospective Observational Cohort Study of Clinical Practice.","authors":"Matthias Bach,&nbsp;Tabea Geisel,&nbsp;Julia Martin,&nbsp;Bettina Schulze,&nbsp;Roland Schaefer,&nbsp;Garth Virgin,&nbsp;Juergen Stein","doi":"10.1155/2015/647930","DOIUrl":"https://doi.org/10.1155/2015/647930","url":null,"abstract":"Current iron supplementation practice in geriatric patients is erratic and lacks evidence-based recommendations. Despite potential benefits in this population, intravenous iron supplementation is often withheld due to concerns regarding pharmacy expense, perceived safety issues, and doubts regarding efficacy in elderly patients. This retrospective, observational cohort study aimed to evaluate the safety and efficacy of intravenous ferric carboxymaltose (FCM, Ferinject) in patients aged >75 years with iron deficiency anaemia (IDA). Within a twelve-month data extraction period, the charts of 405 hospitalised patients aged 65–101 years were retrospectively analysed for IDA, defined according to WHO criteria for anaemia (haemoglobin: <13.0 g/dL (m)/<12.0 g/dL (f)) in conjunction with transferrin saturation <20%. Of 128 IDA patients screened, 51 (39.8%) received intravenous iron. 38 patient charts were analysed. Mean cumulative dose of intravenous FCM was 784.4 ± 271.7 mg iron (1–3 infusions). 18 patients (47%) fulfilled treatment response criteria (≥1.0 g/dL increase in haemoglobin between baseline and hospital discharge). AEs were mild/moderate, most commonly transient increases of liver enzymes (n = 5/13.2%). AE incidence was comparable with that observed in patients <75 years. No serious AEs were observed. Ferric carboxymaltose was well tolerated and effective for correction of Hb levels and iron stores in this cohort of IDA patients aged over 75 years.","PeriodicalId":46055,"journal":{"name":"Anemia","volume":"2015 ","pages":"647930"},"PeriodicalIF":2.9,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/647930","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33889304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
期刊
Anemia
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1